Maggie L. Shaw

Misinformation is not supported by the data on the science of vaccination, agreed experts during “Combating Misinformation in Science,” which took place at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Brian T. Kelly, MD, MA, FACAAI, Midwest Allergy and Asthma Clinic, and the American College of Allergy, Asthma & Immunology annual meeting program chair, discusses the importance of distinguishing between non–immunoglobulin E (IgE)– and IgE-mediated food allergies, as well as remaining up to date on guidance for eosinophilic esophagitis (EoE).

Peter Hotez, MD, PhD, FASTMH, professor of pediatrics and molecular virology and dean, National School of Tropical Medicine, Baylor College of Medicine, and codirector, Texas Children’s Hospital Center for Vaccine Development, addresses antivaccination sentiment and how to overcome it to find an optimal solution to end the COVID-19 pandemic.

Two experts explore disparities in atopic dermatitis by age, skin color, and ethnicity.

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses how small molecule inhibitors are used in atopic dermatitis, as well as why there is no one-size-fits approach to implementing them in practice.

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses the connection between health literacy and lack of trust in science and also addresses allergy concerns toward COVID-19 vaccines.

Investigators compared physical and mental health outcomes among infertile women with and without polycystic ovary syndrome (PCOS), who were considered obese, by looking at their dietary intake, eating behavior, physical activity levels, and quality of life (QOL).

Helen Bygrave, MD, chronic diseases advisor for the Médecins Sans Frontières (MSF; Doctors Without Borders) Access Campaign, explains how the campaign is aiming to eliminate the threat of cryptococcal meningitis among persons living with HIV by 2030.

Individuals with a history of acute myocardial infarction (AMI), or heart attack, may benefit on several fronts following early administration of the neprilysin inhibitor/angiotensin receptor blocker sacubitril/valsartan.

The 2021 ACAAI Annual Scientific Meeting, taking place virtually and in person in New Orleans, kicks off on Thursday, November 4, by focusing on dermatology and atopic dermatitis and concludes on Monday, November 8, with a final plenary session that addresses updates to several treatment guidelines.

Brian T. Kelly, MD, MA, FACAAI, Midwest Allergy and Asthma Clinic, and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting program chair, discusses how this year’s conference content will demonstrate the joint themes of innovation and diversity, as well as what exciting developments presenters and attendees alike should watch for.

Because persons living with HIV (PLWH) are now living longer, issues beyond their positive serostatus are having an adverse impact on their quality of life (QOL), such as obesity; recent research findings note these should be a consideration when choosing how to manage HIV.

Peter Hotez, MD, PhD, FASTMH, professor of pediatrics and molecular virology and dean, National School of Tropical Medicine, Baylor College of Medicine, and codirector, Texas Children’s Hospital Center for Vaccine Development, addresses the approval of the Pfizer/BioNTech COVID-19 vaccine for children aged 5 to 11 and emphasized its benefits far outweigh the rare possibility of myocarditis.

Polycystic ovary syndrome (PCOS) is one of the most common reproductive endocrine and metabolic diseases in women of childbearing age, but data that compare outcomes between obese and nonobese patients are scarce—something this study sought to remedy.

For 3 categories of evaluation, elevated cardiac troponin I levels most influenced the development of myocardial injury among persons at higher lifetime weight totals.

Amanda Ely, CEO, introduces us to The Children's HIV Association (CHIVA) of the United Kingdom and Ireland and details how the experiences of young persons living with HIV differ from those who acquire the virus as adults.

This new study from Serbia compared outcomes on oral glucose tolerance tests between women who are pregnant and those who have polycystic ovary syndrome (PCOS).

Jason Myers, PhD, CEO of the New Zealand AIDS Foundation, delves into how services related to HIV and AIDS in New Zealand—treatment and prevention, and now holistic services—have been spurred to expansion in recent years.

A new study from Turkey shows, among other results, that delayed initiation of treatment with growth hormone among pediatric patients may lead to minimal height improvements despite adherence to the therapy.

With sleep apnea and abnormal sleep patterns typifying Prader-Willi syndrome, researchers from Sweden and Denmark theorized that treatment with growth hormone may improve both for individuals affected by the rare neurodevelopmental disease.

New data presented at IDWeek 2021 show lack of pre-exposure prophylaxis (PrEP) uptake among groups at high risk of HIV infection.

University of Birmingham researchers point to potential benefits via reduced unbound active androgens, low levels of which increase the body’s response to insulin and decrease the likelihood of hirsutism in women with polycystic ovary syndrome (PCOS) at risk of developing type 2 diabetes (T2D).

The American Journal of Managed Care® recently spoke with Nicoleta Dascalu, founding member and advocacy manager of Asociaţia Română Anti-SIDA (ARAS; Romanian Association Against AIDS) to learn more about ARAS, which was founded in April of 1992, just 3 years after the fall of communism in the country.

Focused educational improvements are needed for women of reproductive age and those who are pregnant regarding vertical transmission of HIV and its prevention.

New data on treatment for newly diagnosed pulmonary arterial hypertension (PAH) show initial treatment for the progressive disease that includes macitentan has potential to reduce risk of disease progression.

Research presented at EHA2021 shows that the JAK 1/2 inhibitor ruxolitinib produced cost-effective benefits per quality-adjusted life-year and increased the overall survival rate for patients with myelofibrosis.

Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health and director of the Center for Health, Identity, Behavior and Prevention Studies, discusses how the HIV/AIDS crisis and the ongoing COVID-19 pandemic parallel one another and how both are teaching opportunities.

Christine Ko, MD, professor of dermatology and pathology at Yale University, who specializes in transplant dermatology, explains the considerations involved with skin cancer–related treatment decisions among patients who’ve undergone a solid-organ or other type of organ transplant.

Dawn Averitt, founder of The Well Project and Women's Research Initiative on HIV/AIDS, has been living with HIV for 33 years.